Objective: The 2014 Bethesda System recommends that benign-appearing endometrial cells (BECs) in routine Pap tests should be reported in patients aged ≥45 years. This is a change from previous guidelines to report BECs in women ≥40 years of age. BECs are reported to have 1% chance of endometrial lesion on follow-up. This study tests whether the new threshold may increase the specificity of the test for the detection of clinically significant endometrial lesions. Study Design: After institutional review board approval, 1,177 BECs, reported during an 8-year study period in patients aged ≥40 years, were retrieved from 672,000 routine ThinPrep Pap tests. The results of subsequent workup were collected by chart review, and the Fisher exact test was used to compare results in patients aged <50 and ≥50 years. Results: No endometrial carcinoma and only 2 cases of endometrial hyperplasia were detected in women aged <50 years, whereas 5.5% of women aged ≥50 years with BECs had carcinoma and/or endometrial hyperplasia (p = 0.000169). Conclusion: Investigation of BECs on routine Pap test are useful in patients aged ≥50 years as 5.5% of cases were confirmed to have significant endometrial disease. Our data as well as other studies support raising the BEC-reporting age threshold from ≥45 to ≥50 years, as the new threshold may improve the specificity of the test.

Keywords:
Age limit of reporting, Pap test, 2014 Bethesda System, Endometrial carcinoma, Benign endometrial cells
1.
Kurman RJ, Solomon D: The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnosis: Definitions, Criteria and Explanatory Notes for Terminology and Specimen adequacy. New York, Springer, 1994.
2.
Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-2119.
3.
Nayar R, Wilbur DC: The Pap test and Bethesda 2014. Cancer Cytopathol 2015;123:271-281.
4.
Society AC: 2000 cancer statistics. CA Cancer J Clin 2000;50:1-64
5.
Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
6.
Cibas ES: Cervical and vaginal cytology; in Cibas ES, Ducatman BS (eds): Cytology: Diagnostic Principles and Clinical Correlates, ed 4. Philadelphia, Elsevier Saunders, 2014, pp 50-51.
7.
Cherkis RC, Patten SF Jr, Andrews TJ, et al: Significance of normal endometrial cells detected by cervical cytology. Obstet Gynecol 1988;71:242-244.
8.
Zucker PK, Kasdon EJ, Feldstein ML: The validity of Pap smear parameters as predictors of endometrial pathology in menopausal women. Cancer 1985;56:2256-2263.
9.
Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW, Wender RC: Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2016;66:95-114.
10.
Thrall MJ, Kjeldahl KS, Savik K, Gulbahce HE, Pambuccian SE: Significance of benign endometrial cells in Papanicolaou tests from women aged ≥40 years. Cancer 2005;105:207-216.
11.
Browne T-J, Genest DR, Cibas ES: The clinical significance of benign-appearing endometrial cells on a Papanicolaou test in women 40 years or older. AM J Clinical Pathol 2005;124:834-837.
12.
Papillo JL, Harmon ML, Mount SL: Reporting of endometrial cells in women 40-50 results in increased endometrial biopsies with low yield (abstract). Acta Cytol 2004;48:677-678.
13.
Li Z, Gilbert C, Yang H, Zhao C: Histologic follow-up in patients with Papanicolaou test findings of endometrial cells: results from a large academic women's hospital laboratory. Am J Clin Pathol 2012;138:79-84.
14.
Weiss VL, Cate F, Bloom L, Fadare O, Coogan AC, Desouki MM: Age cut-off for reporting endometrial cells on a Papanicolaou test: 50 years may be more appropriate than 45 years. Cytopathology 2016;27:242-248.
15.
Asciutto KC, Henic E, Forslund O, Bjelkenkrantz K, Borgfeldt C: Age influences the clinical significance of atypical glandular cells on cytology. Anticancer Res 2015.35:913-919.
16.
Kir G, Gocmen A, Cetiner H, Topal CS, Yilmaz MS, Karabulut MH: Clinical significance of benign endometrial cells found in papanicolaou tests of Turkish women aged 40 years and older. J Cytol 2013;30:156-158.
17.
Kapali M, Agaram NP, Dabbs D, Kanbour A, White S, Austin RM: Routine endometrial sampling of asymptomatic premenopausal women shedding normal endometrial cells in Papanicolaou tests is not cost effective. Cancer Cytopathol 2007;111:26-33.
18.
Gold EB: The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am 2011;38:425-440.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.